The global Therapeutic Vaccines Market is valued at USD 31 Billion in 2023 and is projected to reach a value of USD 140 Billion by 2032 at a CAGR (Compound Annual Growth Rate) of 18.2% between 2024 and 2032.
Key Highlights of Therapeutic Vaccines Market
- North America generated more than 55.8% of revenue share in 2023,
- The Asia Pacific region is expected to grow at the quickest rate from 2024 to 2032,
- The Autoimmune Disease vaccines segment accounted for the most considerable market growth in 2023,
- The Autologous Vaccines segment revealed the most significant market growth in 2023,
- The U.S. Department of Health and Human Services (HHS) has invested approximately $1.4 billion in Project NextGen, mainly through the Administration for Strategic Preparedness and Response (ASPR). This funding aims to aid in creating advanced tools and technologies that will safeguard against COVID-19 in the future.
Therapeutic Vaccines Market Size, 2023 To 2032 (USD Billion)
Therapeutic Vaccines Market: Regional Overview
The North American region led the market with a 55.8% market share in 2023. Some of the primary drivers of this trend are the increased incidence of cancer, significant increases in investments in research and development, and a growth in the frequency of new product releases. Notably, information from the American Cancer Society indicates that there will likely be 1.9 million new instances of cancer in the United States in 2022, with 287,850 new cases of breast cancer and roughly 236,740 new cases of lung cancer anticipated. Furthermore, the data shows that there are 268,490 new cases of prostate cancer and 79,000 new cases of kidney cancer. This stark prevalence of cancer underscores a pressing need for Therapeutic Vaccines, as evidenced by the high demand expected for their availability in the United States.
Extensive research is currently underway to improve the stability of therapeutic formulations and adjuvants have been discovered to enhance immune responses and develop more versatile vaccine formulations across the region. Additionally, researchers are exploring the potential of these vaccines to treat other chronic diseases like hypertension and autoimmune disorders. The industry has seen significant investment and partnership activity in recent years, with private and public sector investors providing financial support to organizations conducting research and development. With promising clinical trial results, growing adoption of therapeutic vaccines, and increased investment in R&D, the market for these vaccines is expected to experience substantial growth in the foreseeable future.
U.S. led the North American Therapeutic Vaccines market with a share of more than 65.2% market share in 2023. Research conducted by America's Biopharmaceutical Research Companies reported that in 2013, approximately 300 vaccines were being developed, with a focus on prevention and treatment. These vaccines aimed to address a range of health conditions including allergies, cancer, infectious diseases, and neurological disorders. Additionally, according to the U.S. Centers for Disease Control and Prevention (CDC), therapeutic vaccines have proven successful in reducing the prevalence of around 10 infectious diseases by up to 90% in the United States.
The global Therapeutic Vaccines market can be categorized as Product, Technology, and Region.
- Addiction Vaccines
- Cocaine Addiction Vaccines
- Nicotine Addiction Vaccines
- Autoimmune Disease Vaccines
- Diabetes (Type 1)
- Cancer Vaccines
- Neurological Disease Vaccines
- Parkinson’s Disease Vaccine
- Other Disease Vaccines
- Infectious Disease Vaccines
- Other Infectious Disease Vaccines (outside HIV)
- Hepatitis C
- Autologous Vaccines
- Allogeneic Vaccines
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
|Regions & Countries Covered
- North America - (U.S., Canada, Mexico)
- Europe - (U.K., France, Germany, Italy, Spain, Rest Of Europe)
- Asia Pacific - (China, Japan, India, South Korea, South East Asia, Rest Of Asia Pacific)
- Latin America - (Brazil, Argentina, Rest Of Latin America)
- Middle East & Africa - (GCC Countries, South Africa, Rest Of Middle East & Africa)
- Agenus Inc. (U.S.)
- Argos Therapeutics Inc. (U.S.)
- Bavarian Nordic A/S (Denmark)
- Cel-Sci Corp. (U.S.)
- CSL Ltd. (Australia)
- Emergent Biosolutions Inc. (U.S.)
- GSK PLC (UK)
- Merck & Co. Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Sanofi S.A. (France)
|Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST
analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market
attractiveness analysis by segments and North America, company market share analysis, and COVID-19
Pricing and purchase options
|Avail of customized purchase options to meet your exact research needs. Explore purchase options
Therapeutic Vaccines Market: Product Overview
Autoimmune disease vaccines accounted for the most significant growth of the market in 2023. New treatment solutions are in high demand due to the rising incidence of autoimmune disorders such as psoriasis, multiple sclerosis, and rheumatoid arthritis. As a result, vaccines that change the immune system and try to re-establish immunological tolerance have replaced conventional immunosuppressants as the primary form of treatment. Advanced clinical trials of these vaccines have shown promising safety, efficacy, and symptom control results, which has generated excitement for their upcoming entry into the market. The efficiency of immune system targeting has increased and adverse effects have decreased with the introduction of targeted therapies, such as customized, cell-based, and antigen-specific vaccinations. The expansion of the industry has also been facilitated by technological developments in fields such as gene editing, mRNA, and delivery systems, which have created new avenues for vaccine development.
People suffering from chronic infections who struggle to generate sufficient effective antibodies may benefit from the administration of such vaccines. At present, there are six commercially available melanoma vaccines and therapeutic cancer vaccines, such as Imlygic®, Provenge®, and Tice®, which have recently gained approval for the treatment of melanoma, prostate cancer, and bladder cancer, respectively. Moreover, more than 350 vaccines are currently in development for a range of conditions, including oncological, infectious, hepatological, neurological, and autoimmune disorders.
Therapeutic Vaccines Market: Technology Overview
In 2023, autologous vaccines will account for substantial growth in the Therapeutic Vaccines Market. Autologous vaccines are created using the patient's cells or tissues, offering a targeted therapy that addresses concerns about effectiveness and side effects seen with generalized vaccines. These vaccines promise to treat conditions like cancer, autoimmune diseases, and infectious diseases by boosting the immune system's response. Technological advancements in dendritic cell immunotherapy, mRNA technology, and antigen-specific targeting have contributed to autologous vaccines' precise and efficient design, driving market growth. The goal of new point-of-care manufacturing technologies is to expedite and streamline the process of producing customized vaccines. The autologous vaccines segment represents a transformative opportunity in personalized medicine and contributes to the changing healthcare landscape as technology and regulations progress.
Report Coverage & Deliverables
- Real-Time Data Updates:
- Competitor Benchmarking
- Market Trends Heatmap
- Custom Research Queries
- Market Sentiment Analysis
- Demographic and Geographic Insights
Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool : Vantage Point
- Different types of Therapeutic Vaccines are being developed, including molecular-based, vector-based, and cell-based vaccines. Each type utilizes unique mechanisms to stimulate immune responses. Advancements in molecular, vector, and cell-based vaccines are driving innovation. These vaccines offer high specificity and long-lasting effects.
- There is a need for therapeutic vaccinations that can strengthen the body's immune response against existing infections since chronic diseases have a substantial financial cost. Therapeutic Vaccines are being explored as a new hope for chronic non-communicable diseases. They demonstrate advantages such as high specificity, minimal side effects, and sustained effectiveness.
- Therapeutic Vaccines aim to maximize therapeutic effects while minimizing side effects. Ongoing clinical trials highlight the adaptability of these vaccines, as they induce dynamic immune responses that continue to evolve post-vaccination. This makes them the ultimate personalized therapies.
- Genetic engineering techniques like gene targeting and modification are being utilized to develop Therapeutic Vaccines. These techniques enhance their efficacy and broaden their applications.
- The immunosuppression caused by tumors presents a challenge for Therapeutic Vaccines. Vaccine strategies are being optimized to overcome this challenge. This includes antigen selection, adjuvants, delivery formulations, and combination therapies with other immunotherapies.
- Governments recognize the importance of Therapeutic Vaccines and invest in initiatives to combat infectious diseases. Substantial funding and support from government bodies are accelerating the development of innovative vaccines, clinical trials, and commercial availability.
The Therapeutic Vaccines Market has grown significantly during the analysis period as a result of several reasons, including increasing R&D activities, partnerships, collaborations, product approvals, and product launches. One noteworthy example is the funding received by researchers at the School of Pharmacy, Belfast. In August 2022, Breast Cancer Now provided financial support to explore new treatments with a focus on an aggressive form of breast cancer. The research team received a grant of GBP 228,900 (USD 278,168) to study the protein p53 present in approximately 90% of triple-negative breast cancer tumors. The partnership between the biotechnology startup Orna Therapeutics and Merck (MSD outside of the US and Canada) was another noteworthy development in August 2022. The discovery, development, and commercialization of various oncology and infectious disease projects, including vaccines and treatments, are the goals of this collaboration. Merck will provide an upfront payment of USD 150 million to Orna Therapeutics as part of this collaboration. It is anticipated that these significant amounts of funds and investments will raise demand for Therapeutic Vaccines, which will ultimately support the market's overall expansion. The collective impact of these research initiatives and strategic collaborations will drive the expansion of the market.
As countries invest more in upgrading healthcare and exploring innovative treatments, there's a growing demand for Therapeutic Vaccines. This need is driven by changes in healthcare financing as well as the increase in chronic diseases like cancer, HIV/AIDS, and autoimmune disorders. Governments and insurance providers are realizing that investing in Therapeutic Vaccines can save money in the long run. They will likely introduce policies that make these innovative treatments more affordable to support this. Consequently, this stimulates pharmaceutical companies to allocate resources towards the development and commercialization of Therapeutic Vaccines. Furthermore, the COVID-19 pandemic has hastened the adoption of new technologies, including Therapeutic Vaccines. The urgent need for effective vaccines against the virus has underscored the importance of immunotherapy. This emphasis has triggered more research and development, leading to increased funding and collaborations within the Therapeutic Vaccines market. Therefore, the economic impact involves more than just improving health; it also involves developing a healthcare system that is more responsive and cost-effective.
Key players in the Therapeutic Vaccines Market have made significant developments and received approvals. The NIAID and ASPR's BARDA spearheaded the $5 billion Project NextGen, which received over $1.4 billion in funding from the U.S. Department of Health and Human Services (HHS) in August 2023. The project aims to advance innovative vaccines and therapeutics against COVID-19, demonstrating a strong commitment to public health challenges. Pfizer Inc. achieved a major milestone in August 2023 by receiving marketing authorization from the European Commission for ABRYSVO™, a respiratory syncytial virus (RSV) vaccine. This vaccine provides passive protection to infants through maternal immunization and active immunization for older adults, making significant progress in combating RSV, a potentially severe respiratory virus.
The players in the global Therapeutic Vaccines market include Agenus Inc. (U.S.), Argos Therapeutics Inc. (U.S.), Bavarian Nordic A/S (Denmark), Cel-Sci Corp. (U.S.), CSL Ltd. (Australia), Emergent Biosolutions Inc. (U.S.), GSK PLC (UK), Merck & Co. Inc. (U.S.), Pfizer Inc. (U.S.), Sanofi S.A. (France) among others.
Recent Market Developments
- In August 2023, The U.S. Department of Health and Human Services (HHS), along with the Administration for Strategic Preparedness and Response (ASPR), has granted over $1.4 billion for Project NextGen. This funding aims to aid the creation of advanced tools and technologies that will provide long-term protection against COVID-19.
- In August 2023, Pfizer Inc. has shared that the European Commission (EC) has officially approved ABRYSVO™, a vaccine developed by the company to protect against the respiratory syncytial virus (RSV). This bivalent vaccine is designed to safeguard infants through maternal immunization as well as older adults.
- In June 2023, AstraZeneca and Merck have shared that the U.S. Food and Drug Administration (FDA) has approved for the use of LYNPARZA alongside abiraterone and prednisone or prednisolone (abi/pred) in the treatment of adult patients who have deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC).